Diet, nutrition, and primary and secondary prostate cancer prevention

Primary prostate cancer prevention strategies are ones designed to minimize the risk of getting this cancer in the first place. Secondary prevention strategies are those designed to minimize the risk for disease progression after diagnosis (whether one actually has any form of treatment or one simply follows some form of monitoring strategy). … READ MORE …

New genetic mechanism explains prostate cancer progression in androgen-suppressed patients

According to a media release from Cancer Research UK yesterday, “The first-ever comprehensive study of prostate cancer tissue has revealed a completely new gene network driving the disease in patients who have stopped responding to standard hormone treatment.” … READ MORE …

Predicting metastatic progression of prostate cancer after first-line therapy

The spreading of prostate cancer cells from the prostate to distant sites in the body (“metastasis”) is a critical factor in why prostate cancers lead to patients’ deaths, … but we still don’t really know what triggers prostate cancer cells (or any other cancer cells for that matter) to metastasize. … READ MORE …

Effects of green tea in men with (apparently) low-risk prostate cancer

According to a media release issued last Thursday, a paper presented at a cancer conference in Anaheim, California, last week suggests that men with prostate cancer who drank green tea every day day prior to having a radical prostatectomy had a significant reduction in markers for prostate inflammation. … READ MORE …

Do African Americans do worse than Caucasians on active surveillance?

Data to be presented at the annual meeting of the American Society of Clinical Oncology (ASCO) on Sunday, June 3, suggest that African American men with localized prostate cancer may be less likely that Caucasian men to respond well to active surveillance as a management strategy. However, this conclusion comes from a retrospective analysis of data from a relatively small, single-institution case series. … READ MORE …

Another “Holy Grail” being touted for diagnosis of high-risk prostate cancer: an update

We have now been able to track down a link to detailed information about the article by Yu et al. referred to in yesterday’s commentary under the same heading. … READ MORE …

Newly identified mechanism may affect or control progression of metastatic prostate cancer

According to a media release issued today by the American Association for Cancer Reasearch, a paper just published in Cancer Discovery has suggested that a gene known as PFKFB4 may be implicated in the more aggressive growth of metastatic prostate cancer cells. … READ MORE …

Vigorous exercise may prevent progression of low-risk prostate cancer

The idea that exercise and physicial fitness may be associated with a reduction in risk of disease progression in men with relatively low-risk prostate cancer is hardly new, but … READ MORE …

Dutasteride as a single agent for low-risk prostate cancer

According to data just reported in The Lancet, some men with low-volume, low-risk prostate cancer may be able to delay progression of their disease if treated only with the 5α-reductase inhibitor dutasteride (Avodart®). … READ MORE …

Who needs aggressive treatment after initial radiation … and who does not?

A new report in Lancet Oncology offers guidance on which patients with prostate cancer who are initially treated with radiotherapy and 6 months of neoadjuvant androgen deprivation therapy (ADT) are at relatively high and relatively low levels of risk for prostate cancer-specific mortality. … READ MORE …

U.S. FDA approves NADiA ProsVue prognostic test for prostate cancer

According to a media release issued on Thursday by IRIS International, the U.S. Food & Drug Administration (FDA) has approved the company’s NADiA® ProsVue™ test as a prognostic marker that can “aid in identifying” men at reduced risk for recurrence of prostate cancer in the first 8 years after a prostatectomy. … READ MORE …

Manserin as possible marker of prostate cancer progression

“Manserin” is a novel peptide originally derived from a larger secretory protein called secretogranin II. A newly published paper suggests that expression of manserin in human prostate cancer tissues may correlate with risk for clinically significant and progressive forms of prostate cancer. … READ MORE …

The proposed REALITY trial and the impact of statins on prostate cancer

As a mentioned earlier this week, a new article by Moyad and Klotz has suggested that it may be possible to carry out a randomized clinical trial to evaluate the impact of statin therapy on the progression of early stage prostate cancer. … READ MORE …

Risk associated with rapid rise in PSA immediately following HIFU

An article in the April issue of Clinical Medical Insights: Oncology suggests that a rapid post-treatment increase in the PSA levels of men treated for localized prostate cancer with high-intensity focused ultrasound (HIFU) may indicate later risk for biochemical recurrence. … READ MORE …

Diet, veggies, MEAL, and prostate cancer progression

The issue of whether changes in diet and the use of supplements affect risk for and progression of prostate cancer is regular fodder for media coverage. One of the major problems is that there has never been a large, well-controlled clinical trial that could provide definitive (“level 1″) evidence in support of the clinical benefit of any specific diet. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 867 other followers